August 06, 2020
Article
clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells.
August 06, 2020
Article
Results from a phase 2 trial of pembrolizumab as immune checkpoint inhibition against 5 types of solid tumors show that circulating tumor DNA (ctDNA) may be used to accurately predict response to treatment.
August 01, 2020
Article
The study, using mice, also found that the 2-step therapy was more effective the earlier it was given.
July 31, 2020
Article
The ADAURA trial was stopped in April 2020 after an independent monitoring committee called for the trial to be unblinded 2 years early based on a determination of overwhelming efficacy.
July 24, 2020
Article
Using a computational algorithm, researchers at Children's Hospital of Philadelphia analyzed noncoding genetic mutations to discover how they factor into 5 pediatric cancers.
July 22, 2020
Article
Four studies were highlighted that amplified the 3 components of using genetic testing in cancer treatment and prevention: (1) understanding the germline component of a tumor test, (2) broadening access to genetic counselors with video sessions, and (3) making sure risk assessment of each patient is accurate, so that patients do not have unnecessary surgeries.
July 20, 2020
Article
Featuring findings from the KEYNOTE-177, ARAURA, ASPEN, and CITYSCAPE trials, and new results from MURANO.
July 19, 2020
Article
US cancer researchers benefit from the exchange of information with the World Health Organization (WHO), which helps domestic patients as well as international ones.
July 15, 2020
Article
Pralsetinib, an investigational precision therapy in late-stage development for individuals with alterations in the RET gene, would be jointly sold in the United States by the 2 companies if it is approved.
July 10, 2020
Article
Companion diagnostic testing identifies patients most likely to benefit from biomarker-driven treatments. Much of the promise in lung cancer treatment comes from use of testing to match patients with targeted therapies, checkpoint inhibitors, or combinations.